Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tetanus shot under study in 10,000 people

NCT ID NCT07107932

Prevention Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This large real-world study is testing an injection called siltartoxatug (Sintetol®) to prevent tetanus in people who have been injured. Researchers will follow 10,000 participants for 90 days to see if the shot prevents tetanus and to track any side effects. The goal is to learn how well this treatment works in everyday medical settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
siltartoxatug injection (Sintetol®)
What this could lead to
If successful, this could confirm siltartoxatug as a safe and effective way to prevent tetanus after an injury, potentially replacing current treatments.
What could go wrong
This is an observational registry, not a controlled trial, so results may be less definitive. Side effects are possible, and the study does not compare siltartoxatug to other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients receiving Siltartoxatug for tetanus prophylaxis following injury and providing informed consent for participation.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1.Having received or will receive Siltartoxatug for tetanus prophylaxis following injury; * 2\. Provided signed informed consent by themselves or their legal representatives. Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tetanus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

tetanus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tetanus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shaoxing Central Hospital

    RECRUITING

    Shaoxing, Zhejiang, 312030, China

  • The Second Affiliated Hospital of Shantou University

    NOT_YET_RECRUITING

    Shantou, Guangdong, 515041, China

  • Xiangyun County People's Hospital

    NOT_YET_RECRUITING

    Xiangyun, Yunnan, 672100, China

  • Zhoushan Putuo District People's Hospital

    NOT_YET_RECRUITING

    Zhoushan, Zhejiang, 316100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.